3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Evidence-based management of immune thrombocytopenia: ASH guideline update

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          In 1996 and 2011, the American Society of Hematology (ASH) supported efforts to create guidelines for the diagnosis and management of patients with immune thrombocytopenia (ITP). These guidelines used different approaches to arrive at recommendations for testing and treatment. Despite differences in methodology, in both cases there was a paucity of randomized trials to inform recommendations. As data on the diagnosis and management of ITP expands, the ASH Committee on Quality is dedicated to maintaining updated guidelines representing recent evidence and guideline methodology. Here, we will review the updated ASH guidelines on ITP with a focus on recommendations with new understanding and future research to close knowledge gaps.

          Related collections

          Author and article information

          Journal
          Hematology Am Soc Hematol Educ Program
          Hematology Am Soc Hematol Educ Program
          bloodbook
          bloodbook
          Hematology: the American Society of Hematology Education Program
          American Society of Hematology (Washington, DC )
          1520-4391
          1520-4383
          30 November 2018
          30 November 2019
          : 2018
          : 1
          : 568-575
          Affiliations
          [1 ]Department of Pediatrics, Columbia University Medical Center, New York, NY; and
          [2 ]Imperial College Health Care NHS Trust, Hammersmith Hospital, London, UK
          Author notes
          Correspondence Cindy Neunert, Columbia University Medical Center, Pediatrics, 3959 Broadway, New York, NY 10032; e-mail: cn2401@ 123456cumc.columbia.edu .

          Conflict-of-interest disclosure: N.C. is on the Board of Directors or an advisory committee for Amgen, has consulted for Novartis, has been affiliated with the Speakers Bureau for GSK and Amgen, has been a speaker at educational events organized by Novartis and Amgen, and participates in advisory boards for Amgen, and Novartis. C.E.N. declares no competing financial interests.

          Off-label drug use: None disclosed.

          Article
          PMC6245979 PMC6245979 6245979 01878
          10.1182/asheducation-2018.1.568
          6245979
          30504359
          6483eb6d-7a29-4130-adab-aa30093ad2d6
          © 2018 by The American Society of Hematology. All rights reserved.
          History
          Page count
          Pages: 8
          Categories
          What's Hot in ITP

          Comments

          Comment on this article